Inhibitor of lymphocyte response and immune-related disease

C - Chemistry – Metallurgy – 07 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07K 14/35 (2006.01) A61K 35/18 (2006.01) C07K 7/06 (2006.01) C07K 7/08 (2006.01) C07K 14/47 (2006.01) A61K 38/00 (2006.01) C12N 5/06 (2006.01)

Patent

CA 2071896

2071896 9204049 PCTABS00011 Peptides having at least seven amino acids, preferably up to 20 amino acids, and most preferably 7 to 9 amino acids, comprising an amino acid sequence which corresponds to positions 180-186 of the Mycobacterium tuberculosis protein hsp 65 having the formula TFGLQLE, but differing therefrom by one to three amino acid substitutions in the positions 181-183, are disclosed. These peptides inhibit antigen recognition by T lymphocytes, such as recognition of hsp 65, and are capable of protecting a subject from an immune-related disease, such as autoimmune arthritis and to prevent rejection of a transplanted organ or tissue. Single amino acid substitutions, in particular with alanine, at positions corresponding to hsp 65 positions 183 and 181 are preferred. T cell lines specific for the above peptides and their use in treating or preventing immune-related disease is also disclosed.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Inhibitor of lymphocyte response and immune-related disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitor of lymphocyte response and immune-related disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitor of lymphocyte response and immune-related disease will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1575986

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.